These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 17477470

  • 1. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 2. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
    Straub RH, Pongratz G, Schölmerich J, Kees F, Schaible TF, Antoni C, Kalden JR, Lorenz HM.
    Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
    [Abstract] [Full Text] [Related]

  • 3. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis.
    Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M.
    Arthritis Rheum; 2002 Mar; 46(3):654-62. PubMed ID: 11920401
    [Abstract] [Full Text] [Related]

  • 4. Gonadal hormones in men with rheumatoid arthritis--from onset through 2 years.
    Tengstrand B, Carlström K, Hafström I.
    J Rheumatol; 2009 May; 36(5):887-92. PubMed ID: 19273455
    [Abstract] [Full Text] [Related]

  • 5. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.
    Straub RH, Härle P, Yamana S, Matsuda T, Takasugi K, Kishimoto T, Nishimoto N.
    Arthritis Rheum; 2006 Jun; 54(6):1778-85. PubMed ID: 16729287
    [Abstract] [Full Text] [Related]

  • 6. Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica.
    Cutolo M, Foppiani L, Minuto F.
    J Endocrinol Invest; 2002 Jun; 25(10 Suppl):19-23. PubMed ID: 12508908
    [Abstract] [Full Text] [Related]

  • 7. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
    Cutolo M, Straub RH, Foppiani L, Prete C, Pulsatelli L, Sulli A, Boiardi L, Macchioni P, Giusti M, Pizzorni C, Seriolo B, Salvarani C.
    J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
    [Abstract] [Full Text] [Related]

  • 8. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
    Straub RH, Härle P, Atzeni F, Weidler C, Cutolo M, Sarzi-Puttini P.
    J Rheumatol; 2005 Jul; 32(7):1253-8. PubMed ID: 15996060
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor.
    Zietz B, Reber T, Oertel M, Glück T, Schölmerich J, Straub RH.
    J Rheumatol; 2000 Apr; 27(4):911-8. PubMed ID: 10782815
    [Abstract] [Full Text] [Related]

  • 14. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 15. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [Abstract] [Full Text] [Related]

  • 16. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.
    van Vollenhoven RF, Klareskog L.
    Arthritis Rheum; 2003 Jun; 48(6):1500-3. PubMed ID: 12794816
    [Abstract] [Full Text] [Related]

  • 17. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammation.
    Tengstrand B, Carlström K, Felländer-Tsai L, Hafström I.
    J Rheumatol; 2003 Nov; 30(11):2338-43. PubMed ID: 14677174
    [Abstract] [Full Text] [Related]

  • 18. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Nov; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 19. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P.
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [Abstract] [Full Text] [Related]

  • 20. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM, Pejnovic NN, Sefik-Bukilica MN, Kovacevic LV, Soldatovic II, Damjanov NS.
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.